Posted by Michael Wonder on 27 Apr 2020
Neurocrine Biosciences announces FDA approval of once daily Ongentys (opicapone) as an add-on treatment for patients with Parkinson's disease experiencing "off" episodes
27 April 2020 - Neurocrine Biosciences plans to make Ongentys available to patients later this year.
Neurocrine Biosciences today announced that the U.S. FDA has approved once-daily oral Ongentys (opicapone) 25 mg and 50 mg capsules as an add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes.
As the disease progresses, patients taking levodopa/carbidopa may begin to experience "off" time between treatment doses, during which an increase in Parkinson's disease motor symptoms such as tremor, slowed movement and difficulty walking occur.
